PR1A3

N/A

Report date: 2023/02/18 16:53:06

Base Information

Drug NamePR1A3
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Radioactive diagnostic agent
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsRadionuclide imaging enhancersImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsColorectal NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAntisomaCancer Research UK
Active IndicationsN/A
Inactive IndicationsColorectal NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A